Abstract: A method for assessing cancer comprising obtaining a biological sample of the subject, detecting a level of a C-terminal segment of moesin in the biological sample, wherein the level of the C-terminal segment of moesin detected in the biological sample of the subject is indicative of the subject developing or with an increased probability of developing cancer. The present application also provides a biomarker and a kit for assessing cancer, and uses of such biomarker. The present application also provides a method of treating cancer.

Abstract: A method for assessing sarcoma metastasis comprising obtaining a biological sample of the subject, detecting a level of a N-terminal segment of moesin in the biological sample, wherein the level of the N-terminal segment of moesin detected in the biological sample of the subject is indicative of the subject developing or with an increased probability of developing metastasis of sarcoma. The present application also provides a biomarker and a kit for assessing metastasis of sarcoma, and uses of such biomarker. The present application also provides a method of treating sarcoma metastasis.

Abstract: The present application provides compositions and methods useful for detecting and monitoring autoimmune diseases in a human subject. The methods comprise providing a moesin fragment for binding to an anti-moesin autoantibody and contacting the moesin fragment with a sample obtained from the human subject. The moesin fragment comprises the entire N-terminal FERM domain of a human moesin protein. The human subject has or is suspected of having an autoimmune disease such as connective tissue disease, systemic sclerosis, Sjogren's syndrome, or systemic lupus erythematosus.

Abstract: The present application provides compositions and methods useful for detecting and monitoring acquired aplastic anemia.

Abstract: The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.

Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.

Abstract: The present application provides compositions and methods for modulating the activity and quantity of platelets and preventing and treating disorders or diseases associated with abnormal activity and quantity of platelets.

Abstract: The present application provides compositions and methods for modulating the activity and quantity of platelets and preventing and treating disorders or diseases associated with abnormal activity and quantity of platelets.

Abstract: The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.

Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.

Abstract: The present invention provides compositions and methods useful for detecting and monitoring autoimmune diseases.

Abstract: Provided is an anti-angiogenic fusion protein, which comprises a vascular endothelial cell growth inhibitor (VEGI) or variant thereof, and other polypeptide such as IgG Fc. The fusion protein optionally comprises a linker. The fusion protein can induce the apoptosis of endothelial cells and inhibit the growtth of endothelial cells, so as to be used for treating tumor. Also provided are a pharmaceutical composition and use of the fusion protein.

Abstract: The present application provides compositions and methods useful for detecting and monitoring acquired aplastic anemia.

Abstract: The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fc? 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis.

Abstract: The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fc? 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis.